Search

Displaying results 6601 - 6610 of 10000 in total
  1. Drug

    Atigotatug

    go.drugbank.com/drugs/DB14831
    Investigational

    BMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).

  2. Drug

    Tifacogin

    go.drugbank.com/drugs/DB06437
    Investigational

  3. Drug

    Rebimastat

    go.drugbank.com/drugs/DB06573
    Investigational

  4. Drug

    NVS antibody

    go.drugbank.com/drugs/DB05312
    Experimental

    This drug has been developed using Medarex's UltiMAb Human Antibody Development System to treat autoimmune diseases.

  5. Drug

    Nadide

    go.drugbank.com/drugs/DB14128
    Investigational

    It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)

    Synonyms: Coenzyme I, Cozymase I
  6. Drug

    Talopram

    go.drugbank.com/drugs/DB09190
    Experimental

    Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.

  7. Drug

    MRK-003

    go.drugbank.com/drugs/DB17015
    Experimental

    MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]

    Synonyms: (1'R,4R)-2-(2,2,2-trifluoroethyl)-5'-[(E)-3-[4-(trifluoromethyl)piperidin-1-yl]prop-1-enyl]spiro[1,2,5-thiadiazolidine-4,13'-tricyclo[8.2.1.03,8]trideca-3(8),4,6-triene] 1,1-dioxide
  8. Drug

    LuLym-T

    go.drugbank.com/drugs/DB17405
    Experimental

    LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.

  9. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    It addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the _USH2A_ gene.[L46777] … QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein.

  10. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    ASPA is produced in oligodendrocytes, and participates in the metabolism of N-acetylaspartate (NAA). … It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA).